Journal Article

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A02+ patients: a phase 1 trial

Van Tine, Brian A., Navenot, Jean-Marc, Grand’Maison, Anne, Odunsi, Kunle, Fracasso, Paula M., Everett, John K., Johnson, Melissa L., Annareddy, Thejo, Bai, Jane, Clarke, Jeffrey M., Lin, Quan, Isabelle, Martin, Hong, David S., Trivedi, Trupti, Butler, Marcus O., Tipping, Alex J., Liebner, David A., Bath, Natalie, Wang, Ruoxi, Williams, Dennis, Biswas, Swethajit, Sanderson, Joseph P., Olszanski, Anthony J., Kebriaei, Partow, Bushman, Frederic D., Broad, Robyn, Norry, Elliot, McCarthy, Philip, Sun, Amy, Ghobadi, Armin, Wolchinsky, Zohar, Araujo, Dejka, Fernandes, Lilliam, Naidoo, Revashnee, Elefant, Erica, Blumenschein, George R., Rafail, Stavros, Batrakou, Dzmitry G., Betts, Gareth, McAlpine, Cheryl, Druta, Mihaela, Cashen, Amanda, Karadeniz, Derin, Van Winkle, Erin

2023

Overview

Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in multiple solid tumors. We conducted a multicenter, dose-escalation, phase 1 trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma (SS), ovarian cancer and head and neck cancer ( NCT03132922 ). The primary endpoint was safety, and the secondary efficacy endpoints included overall response rate (ORR) and duration of response. All patients ( N  = 38, nine tumor types) experienced Grade ≥3 hematologic toxicities; 55% of patients (90% Grade ≤2) experienced cytokine release syndrome. ORR (all partial response) was 24% (9/38), 7/16 (44%) for SS and 2/22 (9%) for all other cancers. Median duration of response was 25.6 weeks (95% confidence interval (CI): 12.286, not reached) and 28.1 weeks (95% CI: 12.286, not reached) overall and for SS, respectively. Exploratory analyses showed that afami-cel infiltrates tumors, has an interferon-γ-driven mechanism of action and triggers adaptive immune responses. In addition, afami-cel has an acceptable benefit–risk profile, with early and durable responses, especially in patients with metastatic SS. Although the small trial size limits conclusions that can be drawn, the results warrant further testing in larger studies. In a phase 1 dose-escalation trial in patients with nine different types of solid tumors, MAGE-A4-specific T cells had an acceptable safety profile and exhibited an encouraging overall response rate in patients with synovial sarcoma.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 631/250/1619/554 / 692/699/67/1059/2325 / 692/699/67/1517/1709 / 692/699/67/1536 / 692/699/67/1798 / Antigens / Antigens, Neoplasm / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer Research / Cell therapy / Cell- and Tissue-Based Therapy / Head & neck cancer / Head and Neck Neoplasms / Histocompatibility antigen HLA / HLA-A Antigens / Humans / Immunotherapy, Adoptive - adverse effects / Immunotherapy, Adoptive - methods / Infectious Diseases / Leukocytes / Lymphocytes / Lymphocytes T / Male / Melanoma / Melanoma-associated antigen / Metabolic Diseases / Metastases / Metastasis / Molecular Medicine / Neoplasm Proteins / Neurosciences / Ovarian cancer / Response rates / Risk assessment / Safety / Sarcoma / Solid tumors / Synovial sarcoma / T cell receptors / Therapy / Tumors / γ-Interferon